GIST

Quiz: Which SOC Treatment is an Alternative for Imatinib Intolerant Advanced, mGIST?

11/16/2021

Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.

Approved globally, _______ is...

11/16/2021

Oncology

Sunitinib Displays Safety, Efficacy for Imatinib-Resitant Patients with Advanced GIST

11/15/2021

A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.

A real-world study confirms...

11/15/2021

Oncology

Imatinib Exhibits Viability as Neoadjuvant Therapy for GIST

11/15/2021

Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.

Imatinib is found feasible as...

11/15/2021

Oncology

Conference Coverage

Dose Escalation of Ripretinib Yields OR in Tumor Progressive GIST

11/15/2021

Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.

Investigators sought to evaluate...

11/15/2021

Oncology

Conference Coverage

Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape

09/14/2021

The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.

The ESMO-MCBS medical device was...

09/14/2021

Oncology

Conference Coverage

Driver Mutations Found Targetable for Wild-Type GIST

09/14/2021

Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.

Findings from a recent study...

09/14/2021

Oncology

Conference Insider

Phase 3 INVICTUS Trial Demonstrates Ripretinib Benefit in GIST

09/14/2021

Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...

Mature data released from the...

09/14/2021

Oncology

Videos

Dr Coleman Talks WES of Tumor Tissue, ctDNA in GIST

04/26/2021

Niamh Coleman, MD, PhD, discusses data on whole exome sequencing (WES) of tumor tissue and ctDNA in GIST, presented at the AACR Annual Meeting.

Niamh Coleman, MD, PhD,...

04/26/2021

Oncology

Conference Insider

Genetic Diagnosis Yields Benefit in GIST Therapy

04/20/2021

A patient case study, presented at the 2021 ONS Congress, supports the confirmation that a genetic diagnosis leads to the appropriate management and surveillance approach in GIST, NF1 and other comorbidities, detects the possibility for other...

A patient case study, presented...

04/20/2021

Oncology